Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, August 2005, p. 983-993, Vol. 12, No. 8
1071-412X/05/$08.00+0 doi:10.1128/CDLI.12.8.983-993.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Steve R. Leib,1
Bao Shan Zhang,1,
Robert H. Mealey,2
Wendy C. Brown,1 and
Travis C. McGuire1*
Department of Veterinary Microbiology and Pathology,1 Department of Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington2
Received 22 March 2005/ Returned for modification 19 April 2005/ Accepted 14 May 2005
The effect of immunization with five lipopeptides, three containing T-helper (Th) epitopes and two with both Th and cytotoxic T-lymphocyte (CTL) epitopes, on equine infectious anemia virus (EIAV) challenge was evaluated. Peripheral blood mononuclear cells from EIAV lipopeptide-immunized horses had significant proliferative responses to Th peptides compared with those preimmunization, and the responses were attributed to significant responses to peptides Gag from positions 221 to 245 (Gag 221-245), Gag 250-269, and Pol 326-347; however, there were no consistent CTL responses. The significant proliferative responses in the EIAV lipopeptide-immunized horses allowed testing of the hypothesis that Th responses to immunization would enhance Th and CTL responses following EIAV challenge and lessen the viral load and the severity of clinical disease. The EIAV lipopeptide-immunized group did have a significant increase in proliferative responses to Th peptides 1 week after virus challenge, whereas the control group did not. Two weeks after challenge, a significant CTL response to virus-infected cell targets occurred in the EIAV lipopeptide-immunized group compared to that in the control group. These Th and CTL responses did not significantly alter either the number of viral RNA copies/ml or disease severity. Thus, lipopeptide-induced proliferative responses and enhanced Th and CTL responses early after virus challenge were unable to control challenge virus load and clinical disease.
Present address: Merial Ltd., Athens, GA 30601.
Present address: University of Pittsburgh School of Medicine, 3550 Terrace Street, Pittsburgh, PA 15261.
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»